Affiliation:
1. Clinical Diagnostic Center “Zdorovie” in Rostov-on-Don
2. National Medical Research Centre for Oncology of Minzdrav of Russia
Abstract
Despite the improvement of prostate cancer (PCa) diagnostic methods and the introduction of prostate-specific antigen (PSA) monitoring, the incidence of advanced PCa in Russia remains high. New more informative variables are needed for the effective diagnosis of early stage and high-grade PCa. In the field of epigenetics of special interest is the detection of DNA hypermethylation, which can serve as a PCa biomarker, since it is common to find and may induce a stable appropriate gene silencing, leading to significant cell changes. Aim of the study was to analyze the relationship between methylation of the APC, GSTP1 and RASSF1A genes and total PSA and prostate health index (PHI) in PCa. Material and methods. The present study included 54 patients with suspicion of PCa, up to 75-years old, who had an initial total PSA level from 2.5 to 10 ng/ml. To calculate PHI value the concentrations of total PSA, free PSA and pre-mature form of PSA ([–2]proPSA) in blood serum were measured by chemiluminescence immunoassay. Results and discussion. The study has revealed the statistically significant correlation between the degree of methylation in blood plasma samples and biopsy material of only the GSTP1 gene and PSA-associated markers. We found an increase of parameters contingency as Gleason score increased. Conclusions. As a result of this work, statistically significant direct correlations were identified between changes in methylation patterns of the promoter region of the GSTP1 gene and PHI, which allows us to consider them as potential candidates for inclusion in a diagnostic panel for more effective early detection of prostate cancer.
Publisher
Institute of Cytology and Genetics, SB RAS
Subject
General Biochemistry, Genetics and Molecular Biology
Reference17 articles.
1. Tolkach Y., Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology. 2018;85(1-2):108−116. doi: 10.1159/000477852
2. Prensner J.R., Rubin M.A., Wei J.T., Chinnaiyan A.M. Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med. 2012;4(127):127rv3. doi: 10.1126/scitranslmed.3003180
3. Мassie C.E., Mills I.G., Lynch A.G. The importance of DNA methylation in prostate cancer development. J. Steroid. Biochem. Mol. Biol. 2017;166:1−15. doi: 10.1016/j.jsbmb.2016.04.009
4. Magrupov B.A., Inoyatov U.N. Morphological characteristics of prostate cancer and its assessment using Gleason scale. Vestnik ekstrennoy meditsiny = Emergency Medicine Bulletin. 2020;13(4):50−57. [In Russian].
5. Couñago F., López-Campos F., Díaz-Gavela A.A., Almagro E., Fenández-Pascual E., Henríquez I., Lozano R., Linares Espinós E., Gómez-Iturriaga A., de Velasco G., … Del Cerro E. Clinical applications of molecular biomarkers in prostate cancer. Cancers (Basel). 2020;12(6):1550. doi: 10.3390/cancers12061550